Robert A. Kyle
Impact in
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 496
- Multiple Myeloma Research and Treatments 459
-
- Amyloidosis: Diagnosis, Treatment, Outcomes 292
- Protein Degradation and Inhibitors 97
- Co-authors
- S. Vincent Rajkumar (251 shared papers)Morie A. Gertz (251 shared papers)Angela Dispenzieri (251 shared papers)Philip R. Greipp (152 shared papers)Martha Q. Lacy (238 shared papers)John A. Lust (153 shared papers)Shaji Kumar (247 shared papers)Terry M. Therneau (65 shared papers)
- Journals
- Mayo Clinic Proceedings (245 papers)Blood (158 papers)Journal of Clinical Oncology (54 papers)American Journal of Hematology (45 papers)Leukemia (39 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Robert A. Kyle
1000 papers receiving 61.3k citations
Robert A. Kyle's Hit Papers
Peers
Comparison fields: 5 of 204
- Hematology 34.5k
- Genetics 11.4k
- Oncology 16.6k
- Nephrology 4.1k
- Molecular Biology 33.1k
Countries citing papers authored by Robert A. Kyle
This map shows the geographic impact of Robert A. Kyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Kyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Kyle more than expected).
Fields of papers citing papers by Robert A. Kyle
This network shows the impact of papers produced by Robert A. Kyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Kyle. The network helps show where Robert A. Kyle may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert A. Kyle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.1k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | International Staging System for Multiple Myeloma Hit paper breakdown → | 2005 | 2024 |
| 2 | Review of 1027 Patients With Newly Diagnosed Multiple Myeloma Hit paper breakdown → | 2003 | 1734 |
| 3 | Improved survival in multiple myeloma and the impact of novel therapies Hit paper breakdown → | 2007 | 1722 |
| 4 | A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance Hit paper breakdown → | 2002 | 1065 |
| 5 | Multiple Myeloma Hit paper breakdown → | 2004 | 1045 |
| 6 | Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Hit paper breakdown → | 2013 | 981 |
| 7 | Prevalence of Monoclonal Gammopathy of Undetermined Significance Hit paper breakdown → | 2006 | 972 |
| 8 | Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Hit paper breakdown → | 2008 | 839 |
| 9 | Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Hit paper breakdown → | 2009 | 793 |
| 10 | Multiple myeloma Hit paper breakdown → | 2017 | 792 |
| 11 | Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements Hit paper breakdown → | 2012 | 758 |
| 12 | Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis Hit paper breakdown → | 2004 | 671 |
| 13 | Multiple myeloma Hit paper breakdown → | 2008 | 666 |
| 14 | Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma Hit paper breakdown → | 2007 | 625 |
| 15 | Increased Prevalence and Mortality in Undiagnosed Celiac Disease Hit paper breakdown → | 2009 | 593 |
| 16 | POEMS syndrome: definitions and long-term outcome Hit paper breakdown → | 2003 | 553 |
| 17 | A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine Hit paper breakdown → | 1997 | 517 |
| 18 | Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Hit paper breakdown → | 2005 | 501 |
| 19 | Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System Hit paper breakdown → | 2016 | 501 |
| 20 | Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. | 2002 | 495 |
About Robert A. Kyle
Robert A. Kyle is a scholar working on Hematology, Molecular Biology, Genetics, Oncology and Nephrology, having authored 1.1k papers that have together received 64.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (459 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (292 papers), Chronic Lymphocytic Leukemia Research (145 papers), Protein Degradation and Inhibitors (97 papers), Cancer Treatment and Pharmacology (71 papers), Peptidase Inhibition and Analysis (60 papers), Parathyroid Disorders and Treatments (59 papers) and Lymphoma Diagnosis and Treatment (56 papers). The work is most often cited by research in Hematology (34.5k citations), Genetics (11.4k citations), Oncology (16.6k citations), Nephrology (4.1k citations) and Molecular Biology (33.1k citations). Robert A. Kyle has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include S. Vincent Rajkumar, Morie A. Gertz, Angela Dispenzieri, Philip R. Greipp, Martha Q. Lacy, John A. Lust, Shaji Kumar, Terry M. Therneau, Dirk R. Larson and Rafaël Fonseca. Their work appears in journals such as Mayo Clinic Proceedings, Blood, Journal of Clinical Oncology, American Journal of Hematology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.